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eNOS

:   endothelial NOS

KPSS

:   high potassium physiological salt solution

[l]{.smallcaps}‐NMMA

:   *N* ^G^‐monomethyl‐[l]{.smallcaps}‐arginine

nNOS

:   neuronal NOS

PDRF

:   PVAT‐derived relaxing factor

PSS

:   physiological salt solution

PVAT

:   perivascular adipose tissue

XE 991

:   10,10‐bis(4‐pyridinylmethyl)‐9(10*H*)‐anthracenone dihydrochloride

Introduction {#bph14433-sec-0005}
============

Perivascular adipose tissue (PVAT) surrounds virtually all blood vessels and exerts an anticontractile effect in response to various vasoconstrictor agonists (Gao *et al*., [2007](#bph14433-bib-0022){ref-type="ref"}; Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}). The mechanisms by which PVAT exerts this effect are the subject of intense investigations, and what is clear already from organ bath studies is that adipocytes release transferable relaxing factor(s) (Lohn *et al*., [2002](#bph14433-bib-0034){ref-type="ref"}; Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}). However, the precise identity of these is unclear.

Recent evidence has indicated that <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30> may be involved in the release of PVAT‐derived relaxing factors (PDRFs) provoked by sympathomimetic hormones: Weston *et al*. ([2013](#bph14433-bib-0054){ref-type="ref"}) demonstrated that the specific β~3~‐agonist, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462>, induced endothelium‐independent but PVAT‐dependent myocyte hyperpolarization in rat mesenteric artery via the opening of potassium <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380>.

Vascular smooth muscle cell potassium channels are key regulators of membrane potential, with increased or decreased activity resulting in hyperpolarization or depolarization, respectively, meaning that they act as 'off switches' in excitable cells and occupy a central position in the regulation of vascular tone (Ghatta *et al*., [2006](#bph14433-bib-0025){ref-type="ref"}). Myocyte membrane potential is hyperpolarized in the presence of PVAT, and substantial evidence points towards a role of potassium channels in the anticontractile mechanism. Pharmacological investigations have led to the identification of several potassium channel candidates including <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=81> (Fésüs *et al*., [2007](#bph14433-bib-0021){ref-type="ref"}; Schleifenbaum *et al*., [2010](#bph14433-bib-0048){ref-type="ref"}) and BK~Ca~ (Gao *et al*., [2005](#bph14433-bib-0023){ref-type="ref"}; Lynch *et al*., [2013](#bph14433-bib-0035){ref-type="ref"}), which appear to undergo differential activation depending on the vascular bed and species investigated. Collectively, these studies indicate the emerging importance of PVAT, which appears to exert its anticontractile effect through a variety of complex pathways that may be activated in parallel in response to different agonists.

Therefore, the present studies were designed to investigate the mechanisms responsible for the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=484>‐induced PVAT anticontractile effect. We report that β~3~‐adrenoceptor stimulation of adipocytes leads to Gα~s~ signalling, a rise in <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> and K~v~7 channel activation. The PDRF is <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>.

Methods {#bph14433-sec-0006}
=======

Group sizes {#bph14433-sec-0007}
-----------

For all experiments, the group size is provided within the figure legends. For all experiments, the number of animals is reported. Assays for cAMP and NO were performed in duplicate and an average for each animal used for calculation of mean data.

Randomization {#bph14433-sec-0008}
-------------

All rats used in this study were healthy adult male Sprague Dawley rats bred at Charles River, UK. Rats were randomly assigned to a numbered cage upon delivery from Charles River, and the animals were used when they reached an appropriate size (250--300 g). The pharmacological protocol to be used in each myograph bath was determined prior to mounting the vessels.

Blinding {#bph14433-sec-0009}
--------

Experimental blinding was not used for this study as there was one core experimenter responsible for dissection, experimental protocols and analysis. In order to limit experimental bias, data analysis was not performed until experimental data sets were complete. Duplicate data from a minimum of five separate animals were required for all experimental protocols described.

Normalization {#bph14433-sec-0010}
-------------

Contractile responses are expressed as mean percentages of KPSS constriction ± SEM consistent with previously published data (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}; Withers *et al*., [2011](#bph14433-bib-0059){ref-type="ref"}). This allowed for comparison in contractile changes independent of vessel size.

Validity of animal model {#bph14433-sec-0011}
------------------------

Male Sprague Dawley rats are a well‐established model for the investigation of PVAT function and vascular contractility (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}; Aghamohammadzadeh *et al*., [2013](#bph14433-bib-0001){ref-type="ref"}). The <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1249>‐deficient (eNOS^−/−^) mouse model is well published and commercially available. This model was chosen to confirm the role of eNOS in our proposed mechanism. We have previously shown comparable response of mouse and rat mesenteric arteries to adrenergic stimulation (Withers *et al*., [2011](#bph14433-bib-0059){ref-type="ref"}). Myography protocols detailed below have been validated within our laboratory for rat, mouse and human tissues (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}). Antibodies which were selective for rat antigens were chosen for immunohistochemistry and Western blot studies.

Ethical statement {#bph14433-sec-0012}
-----------------

Experiments involving the use of animals were performed in accord with the UK Animals (Scientific Procedures) Act 1986 under the authority of a valid project licence. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny *et al*., [2010](#bph14433-bib-0031){ref-type="ref"}; McGrath and Lilley, [2015](#bph14433-bib-0036){ref-type="ref"}). The experiments were approved by The University of Manchester Ethical Review Process. All work was carried out in accordance with the Declaration of Helsinki.

Animals {#bph14433-sec-0013}
-------

Healthy male Sprague Dawley rats (250--300 g; Charles River, Harlow, Hertfordshire, UK) were killed by CO~2~ inhalation with death confirmed by permanent cessation of the circulation by severing the diaphragm. The mesenteric bed was immediately removed and placed in ice‐cold physiological salt solution (PSS in mmol·L^−1^: 119 NaCl, 4.7 KCl, 1.17 MgSO~4~, 25 NaHCO~3~, 1.17 KH~2~PO~4~, 0.03 K~2~ EDTA, 5.5 glucose and 1.6 CaCl~2~).

Male eNOS‐deficient (eNOS^−/−^) mice were kindly provided by Dr Elizabeth Cottrell (Manchester, UK). eNOS^−/−^ mice were bred in‐house at the University of Manchester and used at 12‐week‐old. As a control for eNOS^−/−^ mice, age‐matched male C57BL6/j mice were purchased from Envigo, Belton, Leicestershire, UK. Mice were killed as described above. Mesenteric artery samples were obtained and studied as described below.

Wire myography {#bph14433-sec-0014}
--------------

Small mesenteric arteries (internal diameter: 200--300 μm) both with and without PVAT were dissected and mounted on two 40 μm wires in a wire myograph (Danish MyoTech, Aarhus, Denmark, Denmark). The vessels were gassed (95% air/5% CO~2~) and maintained in PSS at 37°C for 30 min before wall tension and diameter were normalized using a standardized procedure (Mulvany and Halpern, [1977](#bph14433-bib-0038){ref-type="ref"}). Isometric tension was continuously recorded (Chart 5, v5.5, AD Instruments, Oxford, Oxfordshire, UK). Vessels were challenged with 60 mmol·L^−1^ high potassium PSS (KPSS in mmol·L^−1^: 63.7 NaCl, 60 KCl, 1.17 MgSO~4~, 25 NaHCO~3~, 1.17 KH~2~PO~4~, 0.03 K~2~ EDTA, 5.5 glucose and 1.6 CaCl~2~) to establish viability, and functional endothelial integrity was assessed by relaxation to 10 μmol·L^−1^ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298> following stable constriction with 10·μmol·L^−1^ noradrenaline.

When investigating the role of the endothelium, endothelium was removed by inserting equine hair into the lumen. Success in removing endothelium was tested using 10 μmol·L^−1^ carbachol as above.

### Pharmacological assessment {#bph14433-sec-0015}

Pharmacological protocols were used to study the mechanisms involved in mediating the PVAT anticontractile effect. In each case, segments from the same artery were prepared with and without PVAT and incubated either with PSS as a vehicle control or PSS containing the pharmacological tool for 30 min. The role of β~3~‐adrenoceptor‐mediated signalling was evaluated by incubation of vessels with the β~3~‐adrenoceptor agonist, CL‐316243, or the β~3~‐adrenoceptor antagonist, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547>. The contribution of NO to PVAT function was assessed by incubation with the non‐specific NOS inhibitor, *N* ^G^‐monomethyl‐[l]{.smallcaps}‐arginine [(l]{.smallcaps}‐NMMA) (Aghamohammadzadeh *et al*., [2013](#bph14433-bib-0001){ref-type="ref"}), and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8830>, which has been shown to be selective for <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1251> at a concentration of 100 nmol·L^−1^ (Babu and Griffith, [1998](#bph14433-bib-0005){ref-type="ref"}). Protocols investigated the contribution of K^+^ channels through incubation with the K~v~7 channel inhibitor -- <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596> (Li *et al*., [2013](#bph14433-bib-0033){ref-type="ref"}).

Following incubation with pharmacological tools, concentration--responses were constructed through the cumulative addition of noradrenaline or phenylephrine to the myograph bath (1 × 10^−7^--3.51 × 10^−5^ mol·L^−1^). The use of these two vasoconstrictor agonists allowed the role of β‐adrenoceptor‐mediated signalling to be investigated, as noradrenaline has equal affinity for α and β‐adrenoceptors, whereas <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485> has higher affinity for <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=4> (Minneman *et al*., [2015](#bph14433-bib-0037){ref-type="ref"}).

### Solution transfer experiments {#bph14433-sec-0016}

Bioassay experiments were used to study the release of relaxing factors from PVAT (Lohn *et al*., [2002](#bph14433-bib-0034){ref-type="ref"}; Gao *et al*., [2007](#bph14433-bib-0022){ref-type="ref"}; Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}). PVAT with and without its adjacent artery was used as a donor, whereas arteries stripped of PVAT were used as recipients. Both the PVAT and recipient arteries were stimulated with 30 μmol·L^−1^ noradrenaline, and once a stable constriction had developed, solutions were removed from both baths and transferred from the bath containing the donor PVAT to the recipient artery without PVAT. The change in tension in the recipient artery was recorded. In order to investigate the contribution of external calcium to the anticontractile mechanism, donor PVAT with and without arteries was stimulated in PSS with (1.6 mmol·L^−1^) and without calcium. In experiments where PVAT was incubated in calcium‐free PSS, the calcium concentration of the solution was restored prior to addition to the recipient artery.

### Exogenous PVAT experiments {#bph14433-sec-0017}

Concentration--responses to noradrenaline were also constructed in vessels devoid of PVAT but with PVAT suspended on a wire within the myograph bath (exogenous PVAT) to enable examination of the release of relaxing factors from PVAT in response to different vasoconstrictor agonists. In some experiments, exogenous PVAT was incubated with various pharmacological tools for 30 min before the return of PVAT to the myograph bath to enable further investigation of PVAT mechanisms. Exogenous PVAT was incubated with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190> to examine the effects of Gαs activation, db‐cAMP to assess the role of cAMP, [l]{.smallcaps}‐NMMA and vinyl‐[l]{.smallcaps}‐NIO to explore the role of PVAT‐derived NO and XE 991 to investigate K~v~7 activation within PVAT.

Stimulation of PVAT {#bph14433-sec-0018}
-------------------

PVAT samples (\~200 mg) were dissected from small mesenteric arteries and incubated in HEPES buffer (pH 7.4, in mmol·L^−1^: 127 NaCl, 5.9 KCl, 1.2 MgSO~4~, 10 HEPES, 2.4 CaCl~2~ and 11.8 glucose) in the absence (control) or presence of noradrenaline (10 μmol·L^−1^) or CL‐316243 (10 μmol·L^−1^) for 30 min at 37°C. The solution surrounding the PVAT (supernatant) was removed, and both tissue and supernatant were snap frozen in liquid nitrogen and stored separately at −80°C until use.

Western blot analysis {#bph14433-sec-0019}
---------------------

In order to investigate the effects of noradrenaline stimulation on downstream signalling within PVAT, Western blot analysis was performed on unstimulated and stimulated PVAT lysate. PVAT samples were homogenized in RIPA buffer containing protease and phosphatase inhibitors using a FastPrep‐24 5G instrument with lysing matrix 5 tubes. Protein concentrations were determined using a Bradford assay. Samples (40 μg of protein) were separated using SDS‐PAGE on a 12% stain‐free SDS‐PAGE gel (Bio‐Rad Laboratories, Watford, Hertfordshire, UK). Following electrophoresis, samples were transferred to a low‐fluorescence PVDF membrane using a Trans‐Blot Turbo system, and transfer was verified using stain‐free imaging. Non‐specific binding sites were blocked with 5% BSA in TBS‐Tween (0.1% Tween), followed by overnight incubation with primary antibody at 4°C. Specific primary antibodies against <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=474> (0.27 μg·mL^−1^), phosphorylated‐AMPKα (0.26 μg·mL^−1^), β~3~‐adrenoceptor (5 μg·mL^−1^) and eNOS (1 μg·mL^−1^) were used. This was followed by three 10 min washes in TBS‐Tween at room temperature and exposure to secondary antibody (donkey anti‐rabbit HRP, 0.8 μg·mL^−1^) for 1 h at room temperature. Protein reactivity was detected using Clarity Western ECL substrate chemiluminescent detection reagent and captured digitally using the ChemiDoc MP imaging system. Stain‐free technology was used as a normalization tool as it allowed normalization to total protein levels through quantification of signal intensity within the whole sample (Ferguson *et al*., [2005](#bph14433-bib-0018){ref-type="ref"}; Gurtler *et al*., [2013](#bph14433-bib-0027){ref-type="ref"}). The chemiluminescent signal intensity of a given protein was normalized to the relative quantification of the corresponding intensity of the total protein, and changes in expression are expressed as the fold increase over unstimulated controls, assigning a value of 1 to the control. Data from each replicate were normalized and then averaged across the replicates, and data are plotted as mean ± SEM.

Immunohistochemistry {#bph14433-sec-0020}
--------------------

PVAT samples were placed in 4% paraformaldehyde for 18 h and subsequently processed to paraffin wax blocks prior to serial sectioning at 5 μm. Samples were de‐waxed using xylene and rehydrated with ethanol prior to immunostaining for <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=563> expression (4 μg·mL^−1^). Heat‐induced antigen retrieval was performed followed by blocking of endogenous peroxidase using 3% H~2~O~2~ and block of non‐specific binding sites using goat serum. Sections were incubated with anti‐K~v~7.4 antibody overnight, followed by 1 h incubation with Biotin‐SP conjugated anti‐rabbit secondary antibody (1.5 μg·mL^−1^) and detection using Vectastain ABC complex followed by the addition of 3,3′‐diaminobenzidine (DAB) solution to allow visualization of antibody binding. Images were captured using a colour camera (Leica DFC450) mounted on a microscope (Leica DM5000).

cAMP assay {#bph14433-sec-0021}
----------

Following stimulation, PVAT samples were homogenized using a FastPrep‐24 5G instrument with lysing matrix 5 tubes in ice‐cold 0.1 mol·L^−1^ hydrochloric acid at a 1:5 ratio (w^.^v^‐1^) to inactivate any PDEs within the sample. Samples were then centrifuged at 1000 *g* for 10 min to remove insoluble cellular debris and neutralized with 1 mol·L^−1^ sodium hydroxide. Samples were diluted 100‐fold in calibrator diluent before intracellular cAMP levels were determined using the competitive enzyme immunoassay cAMP parameter assay kit.

NO levels within PVAT supernatant {#bph14433-sec-0022}
---------------------------------

NO within PVAT supernatant was converted to detectable nitrite by 3 h incubation with nitrate reductase (0.17 U·mL^−1^), glucose‐6‐phosphate dehydrogenase (4.17 U·mL^−1^), glucose‐6‐phosphate (500 μmol·L^−1^) and NADPH (1.67 μmol·L^−1^) as described previously (Verdon *et al*., [1995](#bph14433-bib-0052){ref-type="ref"}). A Griess reagent kit was then used to determine total nitrite concentration.

Total adiponectin ELISA of PVAT supernatant {#bph14433-sec-0023}
-------------------------------------------

Total <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726> levels in stimulated and non‐stimulated PVAT supernatant samples were measured using a commercially available ELISA kit. Stimulated and unstimulated supernatant samples were diluted 1:750 in calibrator diluent before the assay was performed according to the manufacturer\'s instructions.

Data and statistical analysis {#bph14433-sec-0024}
-----------------------------

The data and statistical analysis comply with British Journal of Pharmacology guidelines (Curtis *et al*., [2018](#bph14433-bib-0016){ref-type="ref"}). GraphPad Prism (v6, GraphPad Software, USA) was used for all statistical analyses, and *P* values \< 0.05 were considered statistically significant. Contractile responses are expressed as mean percentages of KPSS constriction ± SEM, consistent with previously published data (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}; Withers *et al*., [2011](#bph14433-bib-0059){ref-type="ref"}), and curves fitted using non‐linear regression analysis. LogEC~50~ values were calculated from individual concentration--response curves fitted using non‐linear regression analysis with a sigmoidal function. Data were analysed using two‐way ANOVA following by Bonferroni *post hoc* test or by Student\'s unpaired or paired *t*‐test as appropriate.

Materials {#bph14433-sec-0025}
---------

### Myography {#bph14433-sec-0026}

All salts for PSSs, noradrenaline, phenylephrine and carbachol were purchased from Sigma‐Aldrich, Gillingham, Dorset, UK. All other pharmacological tools were purchased from R&D Systems, Abingdon, Oxfordshire, UK.

### Western blot analysis {#bph14433-sec-0027}

General consumables were purchased from Sigma‐Aldrich. Reagents for RIPA buffer were purchased from Roche Diagnostics, Burgess Hill, West Sussex, UK. FastPrep‐24 5G instrument was purchased from MP Biomedicals Inc., Santa Ana, California Antibodies used were as follows: AMPKα (Cell Signaling Technology, Hitchin, Hertfordshire, Cat \#2603 RRID: AB_490795), phosphorylated‐AMPKα (Thr^172^) (Cell Signaling Technology, Cat \#2535, RRID: AB_331250), β~3~‐adrenoceptor (Novus Biologicals, Abingdon, Oxfordshire, NBP1‐00716, RRID:AB_1502640), eNOS (Santa Cruz Biotechnology, Dallas, Texas, USA, Cat \#sc‐654 RRID: AB_631423) and donkey anti‐rabbit HRP (Jackson ImmunoResearch Laboratories, Ely, Cambridgeshire, Cat \#711‐035‐152, RRID:AB_10015282). All other Western blot materials were purchased from Bio‐Rad Laboratories.

### Immunohistochemistry {#bph14433-sec-0028}

General consumables were purchased from Sigma‐Aldrich. Antibodies purchased were as follows: K~v~7.4 (Santa Cruz Biotechnology, Cat \#sc‐50 417, RRID: AB_2131729), Biotin‐SP conjugated anti‐rabbit secondary antibody (Jackson ImmunoResearch Laboratories, USA, Cat \#711‐065‐152, RRID: AB_2340593), vectastain ABC complex and DAB solution (Vector Laboratories, Peterborough, Cambridgeshire, UK, ABC: Cat \#PK‐6100, RRID:AB_2336819 DAB: SK‐4100, RRID:AB_2336382).

### Assays {#bph14433-sec-0029}

All general consumables were purchased from Sigma‐Aldrich. The Griess reagent kit was purchased from Promega, Chilworth, Southampton, USA. The cAMP, adiponectin and adipokine assay kits were from R&D systems, Abingdon, Oxfordshire, USA.

Nomenclature of targets and ligands {#bph14433-sec-0030}
-----------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al*., [2018](#bph14433-bib-0028){ref-type="ref"}), and are permanently achieved in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al*., [2017a](#bph14433-bib-0002){ref-type="ref"}, [2017b](#bph14433-bib-0003){ref-type="ref"}, [2017c](#bph14433-bib-0004){ref-type="ref"}).

Results {#bph14433-sec-0031}
=======

PVAT produces a transferable anticontractile factor {#bph14433-sec-0032}
---------------------------------------------------

In endothelium‐intact segments of rat mesenteric small arteries, the vasoconstrictor response to noradrenaline (Figure [1](#bph14433-fig-0001){ref-type="fig"}A) but not phenylephrine was reduced in the presence of PVAT (Figure [1](#bph14433-fig-0001){ref-type="fig"}B). The vasoconstrictor response to noradrenaline was reduced in vessels lacking PVAT with exogenous PVAT suspended in the bath (Figure [1](#bph14433-fig-0001){ref-type="fig"}A), suggesting that the anticontractile effect was due to secretion of a soluble factor.

![The anticontractile capacity of PVAT is produced by secretion of an endothelium‐independent soluble factor. The presence of PVAT reduced the vasoconstrictor response to (A) noradrenaline (*n* = 18). The contractile response to noradrenaline was also reduced in vessels with exogenous PVAT (no PVAT vs. exogenous PVAT: *P* \< 0.05, PVAT vs. exogenous PVAT: *P* = NS, *n* = 5 and 6 respectively). The presence of PVAT had no effect on the vasoconstrictor response to (B) phenylephrine (PVAT *n* = 10, no PVAT *n* = 12). Both donor PVAT and recipient arteries were stimulated with 30 μmol·L^−1^ noradrenaline prior to transfer. (C) Transfer of solution from donor PVAT to a recipient artery lacking PVAT produced a significant reduction in tension both in the presence (*n* = 6) and absence (*n* = 6) of an artery with the PVAT. (D) Transfer of solution from donor PVAT incubated in calcium‐free PSS to a recipient artery produced a significant reduction in tension in the presence and absence of PVAT (*n* = 9) and in the absence of an artery with the PVAT (*n* = 8). The total external calcium concentration of the recipient bath was kept constant at 1.6 mmol·L^−1^ after transfer. (E) The anticontractile effect is absent in endothelium‐denuded arteries (*P* = NS, *n* = 6) Data are expressed as mean ± SEM. \**P* \< 0.05, two‐way ANOVA or paired *t*‐test.](BPH-175-3685-g001){#bph14433-fig-0001}

Transfer of solutions from donor PVAT with and without an artery stimulated with noradrenaline to a recipient artery lacking PVAT pre‐contracted with noradrenaline produced a significant reduction in tension (Figure [1](#bph14433-fig-0001){ref-type="fig"}C), confirming that the anticontractile effect was due to secretion of a soluble factor. Also, relaxation occurred following incubation of donor PVAT with and without an artery in calcium‐free external PSS solution and transfer to a recipient artery, indicating that the anticontractile effect is calcium‐independent (Figure [1](#bph14433-fig-0001){ref-type="fig"}D).

In endothelium‐denuded arteries, the vasoconstrictor response to noradrenaline was not reduced by the presence of PVAT (Figure [1](#bph14433-fig-0001){ref-type="fig"}E), confirming that the anticontractile factor is endothelium‐independent.

Adipocyte located β~3~‐adrenergic activation produces a PVAT‐derived anticontractile effect via Gα~s~ signalling {#bph14433-sec-0033}
----------------------------------------------------------------------------------------------------------------

Western blot analysis indicated the presence of β~3~‐adrenoceptors within the PVAT of rat mesenteric arteries (Figure [2](#bph14433-fig-0002){ref-type="fig"}A); therefore, we investigated the contribution of β~3~‐adrenoceptor‐mediated signalling to the anticontractile effect. The presence of CL‐316243 had no effect on vasoconstrictor response to noradrenaline (Figure [2](#bph14433-fig-0002){ref-type="fig"}B) but reduced the effect of phenylephrine (Figure [2](#bph14433-fig-0002){ref-type="fig"}C), indicating a role for β~3~‐adrenoceptor activation in mediating the anticontractile effect of noradrenaline on PVAT. Incubation of vessels with intact endothelium but lacking PVAT with CL‐316243 had no effect on the vasoconstrictor response to either of the agonists tested (Figure [2](#bph14433-fig-0002){ref-type="fig"}D) confirming that the changes observed are a consequence of β~3~‐adrenoceptor activation within PVAT. Moreover, the β~3~‐adrenoceptor antagonist, SR 59230A, increased the contractile response to noradrenaline in vessels with PVAT (Figure [2](#bph14433-fig-0002){ref-type="fig"}E) but had no effect on the response to phenylephrine (Figure [2](#bph14433-fig-0002){ref-type="fig"}F).

![β~3~‐adrenoceptor activation contributes to the PVAT anticontractile effect. (A) Representative Western blot indicating expression of β~3~‐adrenoceptors within rat mesenteric PVAT. Three independent samples were analysed from each rat on one membrane. Incubation of intact vessels with PVAT with 10 μmol·L^−1^ CL‐316243 for 30 min did not alter the response to (B) noradrenaline (*n* = 5) but enhanced the anticontractile effect of (C) phenylephrine (*n* = 5). (D) Incubation of vessels with endothelium but lacking PVAT with 10 μmol·L^−1^ CL‐316243 did not alter the contractile response to phenylephrine (*n* = 5). Incubation of mesenteric vessels with PVAT with the β~3~‐adrenoceptor antagonist, 1 μmol·L^−1^ SR 59230A for 30 min potentiated constriction to (E) noradrenaline (*n* = 7) but had no effect on the contractile response to (F) phenylephrine (*P* = NS, *n* = 7). Data are expressed as mean ± SEM. \**P* \< 0.05, two‐way ANOVA.](BPH-175-3685-g002){#bph14433-fig-0002}

Incubation of exogenous PVAT with forskolin had no effect on the vasoconstrictor response to noradrenaline (Figure [3](#bph14433-fig-0003){ref-type="fig"}A) but reduced the effect of phenylephrine (Figure [3](#bph14433-fig-0003){ref-type="fig"}B). Incubation with db‐cAMP had no effect on the vasoconstrictor response to noradrenaline (Figure [3](#bph14433-fig-0003){ref-type="fig"}C) but reduced the vasoconstrictor response to phenylephrine (Figure [3](#bph14433-fig-0003){ref-type="fig"}D). Intracellular cAMP levels were increased from 250 ± 33 to 467.4 ± 54 pmol·mL^−1^ within PVAT following stimulation with CL‐316243 indicating that β~3~‐adrenoceptor stimulation involves Gα~s~ signalling (Figure [3](#bph14433-fig-0003){ref-type="fig"}E).

![Gαs signalling contributes to the noradrenaline‐induced PVAT anticontractile effect. Incubation of exogenous PVAT with 1 μmol·L^−1^ forskolin for 30 min prior to placement within the myograph bath had no effect on the vasoconstrictor response to (A) noradrenaline (*n* = 6) but reduced the contractile response to (B) phenylephrine (*n* = 6). Incubation of vessels with PVAT with the cAMP analogue, 10 μmol·L^−1^ db‐cAMP had no effect on constriction to (C) noradrenaline (*n* = 6) but reduced the vasoconstrictor response to (D) phenylephrine (*n* = 6). (E) Intracellular cAMP levels increased following stimulation with 10 μmol·L^−1^ CL‐316243 (*P* \< 0.05, *n* = 6). Data are expressed as mean ± SEM. \**P* \< 0.05, two‐way ANOVA.](BPH-175-3685-g003){#bph14433-fig-0003}

K~v~7 channel activation contributes to noradrenaline‐mediated anticontractile capacity {#bph14433-sec-0034}
---------------------------------------------------------------------------------------

Incubation with the K~v~7 inhibitor, XE 991, did not alter the vasoconstrictor response to noradrenaline in vessels lacking PVAT (Figure [4](#bph14433-fig-0004){ref-type="fig"}A) but potentiated the response to noradrenaline in vessels with PVAT (Figure [4](#bph14433-fig-0004){ref-type="fig"}B). Incubation of exogenous PVAT with XE 991 prior to placement within the myograph bath reversed the anticontractile effect of PVAT (Figure [4](#bph14433-fig-0004){ref-type="fig"}C), indicating that K~v~7 channel activation *within* PVAT contributes to the noradrenaline‐induced anticontractile capacity. Immunostaining for K~v~7.4 shows K~v~7.4 expression within PVAT, the endothelial layer and the adventital layer of the mesenteric artery (Figure [4](#bph14433-fig-0004){ref-type="fig"}D).

![K~v~7 channel inhibition prevents PVAT anticontractile effect. (A) Incubation of vessels lacking PVAT with the K~v~7 inhibitor, XE 991 (10 μmol^.^L^‐1^) for 30 min had no effect on the contractile response to noradrenaline (*n* = 6) but (B) potentiated the contractile response to noradrenaline in vessels with PVAT (*n* = 6). (C) Incubation of exogenous PVAT with XE 991 for 30 min prior to addition to the myograph bath produced an increase in the contractile response in vessels lacking PVAT compared to vessels with control exogenous PVAT (*n* = 5). (D) Immunostaining showed no staining when mesenteric bed samples were incubated with rabbit IgG (a) but clear staining within the PVAT, endothelial layer and adventitial layer of the mesenteric artery when incubated with anti‐K~v~7.4 antibody (b). Images were obtained at 20x magnification and scale bar represents 75 μm. Data are expressed as mean ± SEM. \* *P* \< 0.05, one‐way ANOVA.](BPH-175-3685-g004){#bph14433-fig-0004}

NO produced by adipocytes plays a key role in the anticontractile effect {#bph14433-sec-0035}
------------------------------------------------------------------------

Western blot analysis demonstrated higher eNOS expression within PVAT than the mesenteric artery (Figure [5](#bph14433-fig-0005){ref-type="fig"}A). Incubation with the NOS inhibitor, [l]{.smallcaps}‐NMMA, did not alter the vasoconstrictor response to noradrenaline in vessels with intact endothelium but lacking PVAT (Figure [5](#bph14433-fig-0005){ref-type="fig"}B), but the vasoconstrictor response was increased in the presence of PVAT (Figure [5](#bph14433-fig-0005){ref-type="fig"}C). Incubation of exogenous PVAT with [l]{.smallcaps}‐NMMA prior to placement within the myograph bath increased the vasoconstrictor response to noradrenaline (Figure [5](#bph14433-fig-0005){ref-type="fig"}D), indicating that PVAT‐derived NO may contribute to the noradrenaline‐induced anticontractile capacity. Incubation with [d]{.smallcaps}‐NMMA, an inactive enantiomer of [l]{.smallcaps}‐NMMA, had no effect on the contractile response of vessels with PVAT (Figure [5](#bph14433-fig-0005){ref-type="fig"}E). Incubation of exogenous PVAT with nNOS inhibitor vinyl‐[l]{.smallcaps}‐NIO had no effect on the contractile response (Figure [5](#bph14433-fig-0005){ref-type="fig"}F), indicating that eNOS may be the NOS isoform responsible for NO release from PVAT. Moreover, the anticontractile effect of PVAT on the vasoconstrictor response to noradrenaline present in C57BL6/j mice was absent in eNOS^−/−^, mice indicating that eNOS activation contributes to the release of NO from PVAT (Figure [6](#bph14433-fig-0006){ref-type="fig"}).

![PVAT‐derived NO plays a key role. (A) Representative Western blot showing expression of eNOS within PVAT and mesenteric artery (MA). Kidney (K) was used as a positive control. (B) Incubation of vessels with endothelium but lacking PVAT with either 100 μmol.L‐1 or 200 μmol.L‐1 L‐NMMA had no effect on the contractile response to noradrenaline (n = 5). (C) Incubation with 100 μmol.L‐1 L‐NMMA increased the vasoconstrictor response to noradrenaline in vessels with intact PVAT (n = 6). (D) Incubation of exogenous PVAT with μmol.L‐1 L‐NMMA for 30 min prior to suspension within the myograph bath produced an increase in the contractile response in vessels lacking PVAT compared to vessels with control exogenous PVAT (n = 5). (E) Incubation of vessels with PVAT with D‐NMMA did not alter the contractile response to noradrenaline (n = 5). (F) Incubation of exogenous PVAT with 100 nmol.L‐1 Vinyl‐L‐NIO for 30 min prior to suspension within the myograpth bath had no effect on contractile response (n = 8). Data are expressed mean ± SEM. \* P \< 0.05, two‐way ANOVA.](BPH-175-3685-g005){#bph14433-fig-0005}

![The PVAT anticontractile effect is lost in eNOS^−/−^ mice. (A) In C57BL6/j mice, the vasoconstrictor response to noradrenaline is reduced in the presence of PVAT (*n* = 8). (B) The presence of PVAT had no effect on the vasoconstrictor response to noradrenaline in mesenteric arteries from eNOS^−/−^ mice (*n* = 8). Data are expressed as mean ± SEM. \**P* \< 0.05, two‐way ANOVA.](BPH-175-3685-g006){#bph14433-fig-0006}

β~3~‐Adrenoceptor activation within PVAT does not alter adiponectin release {#bph14433-sec-0036}
---------------------------------------------------------------------------

Abundant amounts of adiponectin were found to be basally secreted from PVAT; however, this was unaltered following stimulation with either noradrenaline or CL‐316243 (Figure [7](#bph14433-fig-0007){ref-type="fig"}).

![Total adiponectin secretion from PVAT is not altered by β~3~‐adrenoceptor activation. Total adiponectin released from PVAT into surrounding solution was not increased by adrenergic stimulation (*n* = 6).](BPH-175-3685-g007){#bph14433-fig-0007}

Discussion {#bph14433-sec-0037}
==========

The present study investigated the mechanisms of the noradrenaline‐induced PVAT anticontractile effect. The main findings were that (i) β~3~‐adrenoceptor‐mediated signalling contributes to the PVAT anticontractile effect; (ii) K~v~7 channel activation *within* PVAT contributes to release of a PDRF; and (iii) PVAT‐derived NO plays a key role in the noradrenaline‐induced PVAT anticontractile effect.

Consistent with previously published data (Briones *et al*., [2005](#bph14433-bib-0009){ref-type="ref"}; Garland *et al*., [2011](#bph14433-bib-0024){ref-type="ref"}; Flacco *et al*., [2013](#bph14433-bib-0019){ref-type="ref"}), we demonstrated no functional role of β~3~‐adrenoceptor‐mediated signalling in the contractile response to noradrenaline in vessels lacking PVAT. This suggests that the effects observed in the present study were a consequence of β~3~‐adrenoceptor activation within the PVAT. This is supported by our previous observations of β~3~‐adrenoceptor expression within mouse mesenteric PVAT and the effects of adipocyte β~3~‐adrenoceptor inhibition on vessel tension (Saxton *et al*., [2018](#bph14433-bib-0047){ref-type="ref"}). In this study, we report a similar β~3~‐adrenoceptor‐mediated mechanism in rat PVAT and have for the first time identified PVAT‐derived NO as a relaxing factor released upon β~3~‐adrenoceptor activation.

Adipocyte β~3~‐adrenoceptors are likely activated by sympathetically derived NA. The role of β~3~‐adrenoceptors in catecholamine induced lipolysis has been well characterized (Bartness *et al*., [2014](#bph14433-bib-0007){ref-type="ref"}; Rebuffe‐Scrive, [1991](#bph14433-bib-0043){ref-type="ref"}; Robidoux *et al*., [2006](#bph14433-bib-0044){ref-type="ref"}), and the origin of sympathetic fibres in epididymal and inguinal fat depots has been extensively studied using viral transneuronal tract tracers (Bamshad *et al*., [1998](#bph14433-bib-0006){ref-type="ref"}; Song *et al*., [2009](#bph14433-bib-0050){ref-type="ref"}; Nguyen *et al*., [2014](#bph14433-bib-0040){ref-type="ref"}). Denervation of these fat depots will lead to a decrease in lipolysis (Rooks *et al*., [2005](#bph14433-bib-0045){ref-type="ref"}; Foster and Bartness, [2006](#bph14433-bib-0020){ref-type="ref"}); however, until recently, the importance of sympathetic nerves in PVAT was unknown. Previously, using immunohistochemistry, we have confirmed the presence of sympathetic nerves in mouse mesenteric PVAT (Saxton *et al*., [2018](#bph14433-bib-0047){ref-type="ref"}). In addition, we confirmed a functional role for sympathetic nerves in PVAT, as pharmacological sympathetic denervation of PVAT abolished the anticontractile effect. Therefore, it is sympathetically derived NA which activates β~3~‐adrenoceptors, triggering the release of a relaxing factor.

Dual coupling of β~3~‐adrenoceptors to both Gα~s~ and Gα~i~ proteins has been reported in 3T3‐F440A adipocytes (Soeder *et al*., [1999](#bph14433-bib-0049){ref-type="ref"}). We highlight an important role of the β~3~‐adrenoceptor/Gα~s~/cAMP signalling pathway in the PVAT anticontractile capacity as β~3~‐adrenoceptor stimulation resulted in cAMP production and incubation with forskolin or db‐cAMP was able to mimic the PVAT anticontractile effect. This is supported by previous studies showing that β~3~‐adrenoceptors within cultured adipocytes have a tendency towards Gα~s~ protein coupling following stimulation with physiologically relevant catecholamine concentrations (Soeder *et al*., [1999](#bph14433-bib-0049){ref-type="ref"}; Robidoux *et al*., [2006](#bph14433-bib-0044){ref-type="ref"}).

Our finding that K~v~7 channel inhibition does not alter the contractile response to noradrenaline in vessels lacking PVAT was surprising given the key role of K~v~7 channels in the regulation of vascular tone (Ng *et al*., [2011](#bph14433-bib-0039){ref-type="ref"}; Chadha *et al*., [2012](#bph14433-bib-0013){ref-type="ref"}). The majority of studies investigating the effect of K~v~7 channel inhibition on vascular tone has reported increased myogenicity in the presence of XE 991 rather than investigating its effect on the arterial response to vasoconstrictor agonists or have demonstrated activation/inhibition of currents using single‐cell electrophysiology in the absence of spasmogens (Ng *et al*., [2011](#bph14433-bib-0039){ref-type="ref"}; Chadha *et al*., [2012](#bph14433-bib-0013){ref-type="ref"}). Moreover, we found very little K~v~7.4 expression within the arterial medial layer consistent with the absence of a functional role, and our data are supported by an earlier myograph study using rat mesenteric artery (Li *et al*., [2013](#bph14433-bib-0033){ref-type="ref"}).

Substantial evidence suggests a role for voltage‐gated K^+^ channels, especially K~v~7 in mediating the PVAT anticontractile effect in resistance arteries (Verlohren *et al*., [2004](#bph14433-bib-0053){ref-type="ref"}; Schleifenbaum *et al*., [2010](#bph14433-bib-0048){ref-type="ref"}; Zavaritskaya *et al*., [2013](#bph14433-bib-0057){ref-type="ref"}). For the first time, we have shown K~v~7.4 expression within PVAT and that specific inhibition of K~v~7 within PVAT reversed the noradrenaline‐induced anticontractile effect in health. This suggests a crucial role for activation of K~v~7 located *within* PVAT in mediating the release of a relaxing factor in health. These findings contradict previous studies that suggested a role for vascular smooth muscle K~v~7 channels in mediating the anticontractile effect (Fang *et al*., [2009](#bph14433-bib-0017){ref-type="ref"}; Schleifenbaum *et al*., [2010](#bph14433-bib-0048){ref-type="ref"}; Zavaritskaya *et al*., [2013](#bph14433-bib-0057){ref-type="ref"}). However, our experimental design allowed specific inhibition of K~v~7 within PVAT without affecting smooth muscle channels enabling identification of the tissue location of the channels involved in the PVAT anticontractile effect. Moreover, previous studies did not investigate K~v~7 expression within PVAT, and on the basis of their results, a role for PVAT K~v~7 activation could not be excluded.

Our data showing a crucial role for K~v~7 within the adipocytes are supported by observations of voltage‐gated K^+^ channels within rat white adipocytes (Ramirez‐Ponce *et al*., [1996](#bph14433-bib-0042){ref-type="ref"}) that can be modulated by noradrenaline and cAMP (Ramirez‐Ponce *et al*., [1998](#bph14433-bib-0041){ref-type="ref"}). Moreover, evidence has emerged that K~v~7 channel activation contributes to the vasodilator response induced by β‐adrenoceptor agonists through a mechanism involving cAMP and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284>, because K~v~7 channel inhibitor linopirdine was able to inhibit relaxations induced by isoprenaline and forskolin (Chadha *et al*., [2012](#bph14433-bib-0013){ref-type="ref"}), and phosphorylation of K~v~7.4 by PKA has been reported to shift the activation curve leading to enhanced K~v~7.4 activity (Chambard and Ashmore, [2005](#bph14433-bib-0014){ref-type="ref"}). Taken together with the observed increased cAMP levels, we suggest that β~3~‐adrenoceptor stimulation within PVAT and subsequent cAMP production leads to K~v~7 activation. This leads to the movement of potassium out of the adipocyte down its electrochemical gradient and hyperpolarization that drives calcium entry with subsequent activation of downstream signalling pathways leading to the release of NO.

Consistent with earlier work, we were able to show that PVAT releases a transferable factor (Lohn *et al*., [2002](#bph14433-bib-0034){ref-type="ref"}; Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}; Lynch *et al*., [2013](#bph14433-bib-0035){ref-type="ref"}), and we demonstrate that this factor is adipocyte‐derived NO as the anticontractile effect reversed in the presence of specific PVAT NOS inhibition and stimulation with CL‐316243, but not phenylephrine increased NO release from PVAT. Consistent with previous studies, the effects of this factor are endothelium‐independent (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}; Saxton *et al*., [2018](#bph14433-bib-0047){ref-type="ref"}).

Several studies have demonstrated a link between β~3~‐adrenoceptor‐mediated signalling and NO production by adipocytes (Canova *et al*., [2006](#bph14433-bib-0012){ref-type="ref"}; Hodis *et al*., [2011](#bph14433-bib-0029){ref-type="ref"}), and recent electrophysiological studies in non‐contracted vessels demonstrated that β~3~‐adrenoceptor‐mediated stimulation of PVAT produced myocyte hyperpolarization that could be partially reversed by the presence of [l]{.smallcaps}‐NMMA (Weston *et al*., [2013](#bph14433-bib-0054){ref-type="ref"}). Moreover, our data support previous findings in human s.c. arteries (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}) and mouse mesenteric arteries (Lynch *et al*., [2013](#bph14433-bib-0035){ref-type="ref"}) where NOS inhibition was reported to attenuate PVAT function, and we have recently shown a crucial role for activation of PKG, a downstream signalling component in the NO pathway, in the noradrenaline‐induced anticontractile effect in mice (Withers *et al*., [2014](#bph14433-bib-0055){ref-type="ref"}).

[l]{.smallcaps}‐NMMA inhibits all three isoforms of NOS (eNOS, nNOS and iNOS) but may also have non‐specific effects. However, the lack of effects of the inactive enantiomer, [d]{.smallcaps}‐NMMA, and the specific nNOS inhibitor, vinyl‐[l]{.smallcaps}‐NIO, strongly suggested that the observed effects of [l]{.smallcaps}‐NMMA in rat PVAT were a consequence of eNOS inhibition. Endothelial NOS (eNOS) plays a key role in white adipose tissue metabolism (Sansbury *et al*., [2012](#bph14433-bib-0046){ref-type="ref"}) and is activated by increased intracellular calcium (Busse and Mulsch, [1990](#bph14433-bib-0011){ref-type="ref"}). Moreover, the PVAT anticontractile effect was absent in eNOS^−/−^ mice, and we were able to detect greater eNOS expression in PVAT than mesenteric artery suggesting that it is the key NOS isoform catalyzing NO production within PVAT.

Adiponectin promotes NO production within the endothelium (Cheng *et al*., [2007](#bph14433-bib-0015){ref-type="ref"}), and previous studies within our laboratory have suggested a key role for adiponectin as a relaxing factor mediating the anticontractile effect in human s.c. (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}) and mouse mesenteric (Lynch *et al*., [2013](#bph14433-bib-0035){ref-type="ref"}) arteries and in response to β~3~‐adrenoceptor‐mediated stimulation of non‐contracted rat mesenteric arteries (Weston *et al*., [2013](#bph14433-bib-0054){ref-type="ref"}). Also, serum levels of adiponectin were increased in rats following 7 day infusion of CL‐316243 (Zhang *et al*., [2002](#bph14433-bib-0058){ref-type="ref"}), and adiponectin secretion from mouse mesenteric PVAT is significantly reduced when incubated with SR 59230A (Saxton *et al*., [2018](#bph14433-bib-0047){ref-type="ref"}). Previously, adiponectin has been shown to induce vasorelaxation in rat (Greenstein *et al*., [2009](#bph14433-bib-0026){ref-type="ref"}) and mouse (Lynch *et al*., [2013](#bph14433-bib-0035){ref-type="ref"}) mesenteric arteries and myocyte hyperpolarization in non‐contracted vessels (Weston *et al*., [2013](#bph14433-bib-0054){ref-type="ref"}). We observed high basal adiponectin secretion from PVAT; however, no changes in total adiponectin secretion were observed following stimulation with noradrenaline or CL‐316243. This may be because biologically relevant changes in the ratio of high MW : low MW isoforms could not be detected using commercially available ELISA kits (Brochu‐Gaudreau *et al*., [2010](#bph14433-bib-0010){ref-type="ref"}). AMPK is a major downstream target of adiponectin (Yamauchi *et al*., [2007](#bph14433-bib-0056){ref-type="ref"}), and we show AMPK phosphorylation in unstimulated PVAT was not altered by β‐adrenoceptor‐mediated stimulation, suggesting that adiponectin may be constitutively released from PVAT and could facilitate NO production by the adipocytes in response to stimulation of β‐adrenoceptors.

The results presented show that adipocyte β~3~‐adrenoceptor stimulation leads to increased intracellular cAMP production and KCNQ activation via increased intracellular calcium leading to release of relaxing factors, one of which is NO (Figure [7](#bph14433-fig-0007){ref-type="fig"}). For the first time, we demonstrate that noradrenaline stimulates release of adipocyte‐derived NO. This NO is a key PDRF and modulates arterial contraction (Figure [8](#bph14433-fig-0008){ref-type="fig"}). These findings support the targeting of NOS for the treatment of PVAT dysfunction associated with obesity and the metabolic syndrome.

![Proposed pathway for nitric oxide release by PVAT and how it results in the PVAT anticontractile effect. Noradrenaline (NA) activates β~3~‐adrenoceptors within PVAT leading to increased cAMP production. This activates K~v~7 within PVAT leading to an efflux of potassium and subsequent hyperpolarisation that drives calcium entry into the adipocyte and activation of endothelial nitric oxide synthase (eNOS) which catalyses the production of NO from L‐arginine (L‐Arg). NO is released from PVAT and acts on vascular smooth muscle cells leading to hyperpolarisation and vasodilatation which opposes vasoconstriction resulting in an anticontractile effect.](BPH-175-3685-g008){#bph14433-fig-0008}
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